Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.
Tari King, MD, FACS
Advertisement
Articles by Tari King, MD, FACS
Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses surgical approaches in breast cancer.
Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses approaches to treating lymphedema in patients with breast cancer.
Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses axillary node dissection in patients with breast cancer.
Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.
Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses lymph node resection in breast cancer.
Advertisement
Latest Updated Articles
Dr. King Discusses Lymph Node Resection in Breast CancerPublished: December 14th 2017 | Updated:
Dr. King on Role of Sentinel Lymph Node Biopsy in Breast CancerPublished: January 30th 2018 | Updated:
Dr. King Discusses Axillary Node Dissection in Breast CancerPublished: February 14th 2018 | Updated:
Dr. King Discusses Approaches to Lymphedema in Breast CancerPublished: March 10th 2018 | Updated:
Dr. King on Surgical Approaches in Breast CancerPublished: October 17th 2018 | Updated:
Dr. King on Neoadjuvant Chemotherapy in Breast CancerPublished: October 5th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5